Arch Oncology 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  AO-176 / Arch Oncology
    Trial completion, Enrollment change, Trial primary completion date:  KEYNOTE-C49: AO-176 in Multiple Solid Tumor Malignancies (clinicaltrials.gov) -  Aug 22, 2023   
    P1/2,  N=57, Completed, 
    Active, not recruiting --> Completed | N=157 --> 10 | Trial completion date: Mar 2024 --> Nov 2022 Active, not recruiting --> Completed | N=183 --> 57 | Trial primary completion date: Mar 2023 --> Nov 2022
  • ||||||||||  AO-176 / Arch Oncology
    Enrollment closed:  KEYNOTE-C49: AO-176 in Multiple Solid Tumor Malignancies (clinicaltrials.gov) -  Aug 5, 2022   
    P1/2,  N=183, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
  • ||||||||||  AO-176 / Arch Oncology
    Journal:  Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells. (Pubmed Central) -  Jul 21, 2021   
    P1/2
    Finally, both Abs also enhance phagocytosis when combined with tumor-opsonizing Abs, including a highly differentiated anti-CD47 Ab, AO-176, currently being evaluated in phase 1 clinical trials, NCT03834948 and NCT04445701 SIRP-1 and SIRP-2 are novel, differentiated SIRP Abs that induce in vitro single-agent and combination phagocytosis and show no adverse effects on T cell functionality. These data support their future development, both as single agents and in combination with other anticancer drugs.
  • ||||||||||  AO-176 / Arch Oncology
    Enrollment change, Trial completion date, Trial primary completion date:  KEYNOTE-C49: AO-176 in Multiple Solid Tumor Malignancies (clinicaltrials.gov) -  Jul 8, 2021   
    P1/2,  N=183, Recruiting, 
    These data support their future development, both as single agents and in combination with other anticancer drugs. N=132 --> 183 | Trial completion date: Jul 2021 --> Mar 2023 | Trial primary completion date: Apr 2021 --> Mar 2023
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] AO-176, a highly differentiated clinical stage anti-CD47 antibody, is efficacious in pre-clinical models of lymphoma () -  Mar 11, 2021 - Abstract #AACR2021AACR_2049;    
    P1/2
    We also demonstrate that AO-176 is a potent tumor growth inhibitor in lymphoma xenograft models and appears to induce immune infiltrates as well as inflammatory cytokines.Taken together, these data show that AO-176 has strong therapeutic potential in lymphoma. AO-176 is currently being evaluated in clinical trials of select solid tumors (NCT03834948) and multiple myeloma (NCT04445701).
  • ||||||||||  AO-176 / Arch Oncology
    Enrollment change:  KEYNOTE-C49: AO-176 in Multiple Solid Tumor Malignancies (clinicaltrials.gov) -  Sep 19, 2020   
    P1/2,  N=132, Recruiting, 
    AO-176 is currently being evaluated in Phase 1 clinical trials for the treatment of patients with select solid tumors (NCT03834948) and multiple myeloma (NCT04445701). N=90 --> 132
  • ||||||||||  Darzalex IV (daratumumab) / J&J, Rituxan (rituximab) / Roche, Biogen
    Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_2689;    
    P1
    In combination with agents targeting CD20 (rituximab) or CD38 (daratumumab), AO-176 mediates enhanced phagocytosis of lymphoma and multiple myeloma cell lines, respectively...When combined with bortezomib, AO-176 was able to elicit complete tumor regression (100% CR in 10/10 animals treated with either 10 or 25 mg/kg AO-176 + 1 mg/kg bortezomib) with no detectable tumor out to 100 days at study termination...With AO-176’s highly differentiated MOA and binding characteristics, it may have the potential to improve upon the safety and efficacy profiles relative to other agents in this class. AO-176 is currently being evaluated in a Phase 1 clinical trial (NCT03834948) for the treatment of patients with select solid tumors.
  • ||||||||||  AO-176 / Arch Oncology
    Novel SIRP antibodies with differentiated characteristics for targeting innate immunity in cancer (Prince George's Exhibition Halls AB) -  Oct 2, 2019 - Abstract #SITC2019SITC_1113;    
    Our novel anti-SIRP antibodies induce promising and differentiated in vitro single agent and combination phagocytosis and show no adverse effects on T cell functionality. These data support their future development, both as single agent antibodies and in combination with other anti-cancer drugs.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, paclitaxel / Generic Mfg.
    AO-176, a highly differentiated humanized anti-CD47 antibody, exhibits single-agent and combination antitumor efficacy with chemotherapy and targeted antibodies (Board 100: Level 2 - Hall D) -  Sep 18, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_335;    
    P1
    In combination with the chemotherapeutics paclitaxel and cisplatin, AO-176 also potentiated direct tumor killing of gastric cancer cells in vitro...With a highly differentiated mechanism of action and binding profile, AO-176 may have the potential to improve upon the safety and efficacy profiles relative to other agents in this class. AO-176 is currently being evaluated in a Phase 1 clinical trial (NCT03834948) for the treatment of patients with select solid tumors.